6AN (6-Aminonicotinamide)

Catalog No.S9783 Batch:S978301

Print

Technical Data

Formula

C6H7N3O
Molecular Weight 137.14 CAS No. 329-89-5
Solubility (25°C)* In vitro DMSO 27 mg/mL (196.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
1.25mg/ml Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description 6AN (6-Aminonicotinamide) is an antimetabolite used to inhibit the NADPH-producing pentose phosphate pathway (PPP) in many cellular systems, making them more susceptible to oxidative stress. 6-Aminonicotinamide is a competitive inhibitor of NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) with Ki of 0.46 μM.
Targets
G6PD [1]
(Cell-free assay)
0.46 μM(Ki)
In vitro

Blocking the pentose phosphate pathway (PPP) by 6-AN significantly inhibits mES colony formation in the presence of a normal concentration of glucose. 6-AN treatment effectively inhibits AKT phosphorylation and activation of its downstream effector S6. 6-AN treatment has no effect on the ERK and PDK1 activities, suggesting an AKT-specific effect. 6-AN treatment inhibits cell growth.[2]
In vivo

PTEN null human cancer cells and in vivo murine models are sensitive to 6-AN (anti-PPP, anti pentose phosphate pathway) treatments, suggesting the importance of the PPP in maintaining AKT activation even in the presence of a constitutively activated PI3K pathway. The treatment of TALL models with 6-AN significantly increases the Phlda3 mRNA and protein levels, accompanied by substantial decreases in the levels of P-AKT and P-S6 as well as the PPP metabolic intermediates.[2]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    HeLa cells, mES cells

  • Concentrations

    100 nM

  • Incubation Time

    24 h, 2 days, 3 days, 4 days

  • Method

    PHLDA3 knockout blocks the effects of 6-AN, R5P or uridine on cell growth in vitro. Isogenic PHLDA3 WT and knockout HeLa cells are seeded in 96-well plates at a density of 1000 cells/well. After 48 h, the cells are treated with 6-AN (100 nM). Cell viability is detected by CCK-8 assays at indicated time points.
Animal Study:

[2]
  • Animal Models

    male CAnN.Cg-Foxn1nu/CrlVr mice

  • Dosages

    1 mg/kg, 15 mg/kg

  • Administration

    IP

Selleck's 6AN (6-Aminonicotinamide) has been cited by 10 publications

Therapeutic modulation of ROCK overcomes metabolic adaptation of cancer cells to OXPHOS inhibition and drives synergistic anti-tumor activity [ bioRxiv, 2024, 2024.09.16.613317] PubMed: 39345502
Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer [ Cell Rep Med, 2023, S2666-3791(23)00315-4] PubMed: 37597521
Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer [ Cell Rep Med, 2023, 4(9):101162] PubMed: 37597521
PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer [ Cell Death Dis, 2023, 14(10):652] PubMed: 37802999
PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer [ Cell Death Dis, 2023, 14(10):652] PubMed: 37802999
Aberrant metabolite trafficking and fuel sensitivity in human pluripotent stem cell-derived islets [ Cell Rep, 2023, 42(8):112970] PubMed: 37556323
Insulin-induced gene 2 protects against hepatic ischemia-reperfusion injury via metabolic remodeling [ J Transl Med, 2023, 21(1):739] PubMed: 37858181
Insulin-induced gene 2 protects against hepatic ischemia-reperfusion injury via metabolic remodeling [ J Transl Med, 2023, 21(1):739] PubMed: 37858181
Metabolic heterogeneity protects metastatic mucosal melanomas cells from ferroptosis [ Int J Mol Med, 2022, 50(4)124] PubMed: 36004461
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase [ Cancer Metab, 2020, 8:19] PubMed: 32974013

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.